Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Phase 2 Recruiting 59 enrolled Women's Hospital School Of Medicine Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Timeline

Start: 2025-03-10
Primary completion: 2026-12-31
Completion: 2029-12-31

Publications

Chen L, Chen T, Tu N, Dong L, Zhang Y, Wang H, Shen Y. Camrelizumab combined with chemotherapy as postoperative adjuvant therapy after radical surgery for cervical cancer patients with pathologically positive lymph nodes: a prospective multicenter phase II clinical trial. J Gynecol Oncol. 2026 Jul 9. doi: 10.3802/jgo.2027.38.e1. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	—
Subject	Cisplatin	Other / unclassified	75 mg/m2	—
Subject	Cisplatin	Other / unclassified	80 mg/m2	—
Subject	Paclitaxel	Small molecule	175 mg/m2	—

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Summary

Timeline

Publications

Drugs

Indications